MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Assertio Holdings General and Administrative Expenses 2011-2025 | ASRT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Assertio Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.6 M | 46.8 M | 52.6 M | 104 M | - | - | - | - | - | - | 105 M | 97.6 M | 54.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 46.8 M | 77.1 M |
Quarterly General and Administrative Expenses Assertio Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.9 M | 17 M | 22 M | - | 16.7 M | 18.4 M | 18.5 M | - | 21 M | 16.8 M | 16.9 M | - | 11.9 M | 10.5 M | 10.6 M | - | 9.01 M | 24 M | 8.32 M | - | 27.6 M | 28.1 M | 27.3 M | - | 36.1 M | 24.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.1 M | 8.32 M | 19.1 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
170 M | $ 1.69 | -3.16 % | $ 182 M |  Canada |
 |
Alimera Sciences
ALIM
|
18.5 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
138 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
8.53 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
95.9 M | $ 3.05 | -6.72 % | $ 1.63 B | Canada |
 |
Agile Therapeutics
AGRX
|
10.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
119 M | $ 5.17 | -4.22 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
935 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
390 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
58.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
14.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
107 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
295 M | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Endo International plc
ENDP
|
568 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
368 M | $ 12.03 | 5.34 % | $ 616 M | USA |
 |
Pacira BioSciences
PCRX
|
294 M | $ 26.7 | 1.56 % | $ 1.23 B | USA |
 |
Evoke Pharma
EVOK
|
12.2 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
44.9 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
181 M | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Rockwell Medical
RMTI
|
12.1 M | $ 0.87 | -5.71 % | $ 20.3 M | USA |
 |
Evolus
EOLS
|
198 M | $ 7.18 | 1.92 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
83.1 M | $ 45.82 | -2.64 % | $ 1.49 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
7.36 M | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
China Pharma Holdings
CPHI
|
1.78 M | $ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
2.92 B | $ 6.88 | -0.65 % | $ 2.51 B | Canada |
 |
Veru
VERU
|
31.2 M | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Lannett Company
LCI
|
81 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
12.8 M | $ 1.8 | -6.51 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
11.1 M | $ 3.05 | 20.47 % | $ 42.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
11.2 M | - | - | $ 193 M | Canada |
 |
Solid Biosciences
SLDB
|
33.3 M | $ 5.81 | -1.11 % | $ 237 M | USA |
 |
PetIQ
PETQ
|
196 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
48.9 M | $ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
468 M | $ 12.86 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
34.4 M | $ 0.12 | 0.17 % | $ 1.9 M | USA |
 |
Radius Health
RDUS
|
131 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
21 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
38.4 M | $ 1.96 | -11.31 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
79.8 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
40 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
20.9 M | $ 0.64 | -1.25 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
37.6 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
165 M | $ 11.6 | -4.56 % | $ 7.17 B | Canada |
 |
TherapeuticsMD
TXMD
|
8.9 M | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
29 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
4.18 B | $ 11.66 | 0.09 % | $ 14.1 B | USA |